Space Mirrors, AI Drug Credit: Key Tech Threats & Wins
▼ Summary
– Reflect Orbital plans to launch test satellites with large mirrors to reflect sunlight to Earth for various applications.
– The proposed space mirrors could cause significant light pollution, potentially affecting aviation, wildlife, and dark skies.
– Insilico Medicine claimed generative AI discovered a drug but listed only humans as inventors on the patent application.
– Current intellectual property laws restrict patent rights to human inventors, regardless of AI involvement in the discovery process.
– As AI becomes more capable in drug design, legal frameworks may need to evolve to address complex questions of invention credit.
Space-based solar mirrors and the legal status of AI-generated pharmaceuticals are emerging as critical flashpoints in the technology sector. Reflect Orbital is preparing to deploy a test satellite later this year that will unfurl an 18-by-18-meter mirror into orbit. The company’s long-term vision involves deploying up to 50,000 larger satellites capable of reflecting sunlight to Earth on demand. While the firm argues this technology could boost solar panel efficiency, aid emergency response efforts, and support military operations, independent research highlights significant environmental and safety risks. Studies indicate these beams could be as bright as 10,000 full moons, scattering light over tens of kilometers and potentially disrupting dark skies, aviation, and wildlife.
In the pharmaceutical industry, the rise of generative AI is challenging traditional concepts of intellectual property. When Insilico Medicine utilized its computer models to identify a promising treatment for pulmonary fibrosis, the company publicly stated the molecule had been “discovered by” generative AI. However, the patent application told a different story. The filing omitted any reference to artificial intelligence, instead listing five humans as the drug’s “inventors.” This contradiction underscores a rigid reality in current law: only humans can claim ownership of an invention, regardless of how central AI was to the process. As AI systems become increasingly adept at designing drugs, patent offices may soon face complex questions regarding the true nature of invention and authorship.
(Source: MIT Technology Review)